What is HIDI?

ICER recently released a white paper titled “Advancing Health Technology Assessment Methods that Support Health Equity“. In addition to discussing a variety of methods–e.g., distributional cost-effectiveness analysis (DCEA), extended cost effectiveness analysis, multi-criteria decision analysis (MCDA)–for quantifying the value of new treatments in terms of their ability to reduce health disparities, ICER also introduces the…

Steps Health Professionals Can Take to Reduce Inequality in Health Outcomes

That is the title of an article in AJMC co-authored with Meena Venkatachalam. An excerpt is below: While decision-makers traditionally have ignored the issue of inequality, academic researchers have already developed tools to quantify a treatment’s value from reductions in inequality. Two common methods for doing so are distributional cost effectiveness analysis (DCEA) and multiple-criteria…

Using HEOR Methods to Reduce Health Inequalities

Join me tomorrow, 9/26, 12:00 PM EDT, as PRECISIONheor’s Jason Shafrin and Meena Venkatachalam discuss their recent blog commentary in the health policy journal Health Affairs on how novel methods of Cost-Effectiveness Analysis can be used to expand traditional value frameworks improve health outcomes for underserved communities. Moderated by Precision’s Kelly Wilder, there will be a live Q&A following the webinar.…

What is MCDA and why do we need it?

Value measurement using cost-effectiveness analysis (CEA) is one of the core stables of health economic research.  CEA often uses quality adjusted life years (QALYs) to capture how a treatment affects a patients mortality and morbidity.  CEA makes explicit assumptions about the tradeoffs between mortality and morbidity by assuming these are additive.  Further, this approach, however,…

Are open-source approaches to value measurement the wave of the future?

My colleagues Jeroen Jansen, Devin Incerti along with Jeff Curtis think so. In JMCP they write: In the United States, there is an increased interest to understand the value of health technologies. Cost-effectiveness analysis is arguably the most appropriate framework to quantify value and to inform reimbursement decision making regarding medical interventions; however, a thorough…